437950.fig.001a
(a)
437950.fig.001b
(b)
437950.fig.001c
(c)
437950.fig.001d
(d)
437950.fig.001e
(e)
437950.fig.001f
(f)
437950.fig.001g
(g)
437950.fig.001h
(h)
Figure 1: Transwell in vitro invasion assay detects the effect of ulinastatin on the invasive ability of colon cancer cells. (a) Control group without reagents; (b) low-dose ulinastatin (L-UTI) group, 800 U/mL ulinastatin; (c) high-dose ulinastatin (H-UTI) group, 8000 U/mL ulinastatin; (d) IL-1α (10 ng/mL) + plasminogen group (10 μg/mL); (e) IL-1α (10 ng/mL) + plasminogen (10 μg/mL) + L-UTI group (800 U/mL); (f) IL-1α (10 ng/mL) + plasminogen (10 μg/mL) + L-UTI group (8000 U/mL); (g) GM6001 group (0.8 nmol/L).